ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
NICE approves first immunotherapy combination for advanced bowel cancer patients with rare MSI-H/dMMR mutation
June 15, 2021Bristol Myers Squibb (BMS) today announced that the National Institute for Health and Care Excellence (NICE) has issued a Final Appraisal Document (FAD) recommending the combination of nivolumab plus ipilimumab for advanced colorectal (bowel) cancer.
Pharma Sources Insight January 2025
